Entinostat (MS-275)

目录号:S1053 别名: SNDX-275

Entinostat (MS-275) Chemical Structure

Molecular Weight(MW): 376.41

Entinostat (MS-275)强烈抑制HDAC1HDAC3,无细胞试验中IC50分别为0.51 μM和1.7 μM,抑制作用强于HDACs 4, 6, 8,和10。Phase 3。

规格 价格 库存 购买数量  
RMB 746.45 现货
RMB 564.33 现货
RMB 1233.32 现货
RMB 2234.07 现货
RMB 6301.79 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户购买Selleck的此次产品后发表的文献62篇:

客户使用该产品的14个实验数据:

  • (A) U87 cells were cultured in the presence of DMSO, 1 uM MS-275 alone, 100 ng/ml IFN-λ1 alone, or both for the course of 4 d. Cell numbers were manually determined by hemacytometer counting at the indicated time points. (B, F) Cell proliferation of U87 cells or U87 spheroids in 3D culture with indicated treatment were performed using the WST-1 assay, which measures active cellular metabolism. (C) U87 spheroid formation in 3D culture was photographed at day 14 in culture (representative images are shown; 200x magnification). (D-E) Quantification of the relative sizes and numbers of U87 spheroids in (C). (G) Cell cycle analysis was performed in U87 cells with indicated treatment using propidium iodide staining. Numbers in the histogram show fractions (percent) of sub-G1, N, 2N, and polyploidy from left to right. (H) U87 cells with indicated treatment were stained with Annexin V-FITC and 7-AAD. Numbers indicate the percentage of FITC-positive cells (upper left quadrant). FITC, fluorescein isothiocyanate; 7-AAD, 7-Aminoactinomycin. In all panels, data represent the mean and SEM of at least three experiments.

    PLoS Biol 2014 12, e1001758. Entinostat (MS-275) purchased from Selleck.

    Inhibition of HDAC1-mediated DNMT1 deacetylation promotes DNMT1 proteasomal degradation. (A) Knockout of HAUSP potentiates HDAC inhibitor (HDACi)-induced DNMT1 degradation. Parental or HAUSP KO DLD1 cells were treated or not with 5 μM HDACi MS-275 for 72 hours and cell lysates were blotted with the indicated antibodies. (B) HDAC inhibition induces DNMT1 ubiquitination. HAUSP WT or KO cells were treated with or without HDACi for 24 hours and MG132 for 12 hours before being harvested to make cell lysates. DNMT1 immunoprecipitates were blotted with an antibody against ubiquitin. Because the abundance of DNMT1 in the HAUSP KO cells is lower than in WT cells, more KO cells were used than WT cells to obtain equal amounts of precipitated DNMT1 proteins. (C) DNMT1 is acetylated after HDACi treatment. DNMT1 immunoprecipitates from cells treated with HDACi were blotted with an antibody against acetylated lysine (Ac-K). (D) A DNMT1 acetylation site mutant is resistant to HDACi-induced degradation. HEK 293 cells were transfected with WT DNMT1 or a DNMT1 mutant lacking four known acetylation sites (K173R, K1113R, K115R, and K117R) and treated with MS-275 for 48 hours and with CHX for 24 hours. Cell lysates were blotted with the indicated antibodies. (E) Knockdown of HDAC1 decreases the abundance of DNMT1. RKO cells were treated with the indicated concentration of doxycycline (Dox) for 48 hours to induce expression of an shRNA directed against HDAC1. Western blots were performed with the indicated antibodies. (F) Knockdown of HDAC1 leads to increased acetylation of DNMT1. RKO cells expressing an inducible HDAC1 shRNA were treated with or without Dox (4 mg/ml) for 36 hours and then with MG132 for 12 hours. DNMT1 immunoprecipitates were blotted with an antibody against Ac-K. Cell lysates were also blotted with antibodies against HDAC1 and b-actin.

     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

  • The E3 ligase UHRF1 ubiquitinates DNMT1. (A) HDAC inhibition enhances DNMT1 interaction with UHRF1. HEK 293 cells were transfected with plasmids expressing Myc-DNMT1 and Flag-UHRF1 and treated with or without MS-275 for 24 hours. Myc-DNMT1 immunoprecipitates were blotted with the indicated antibodies. (B and C) HDAC inhibition enhances the interaction of endogenous DNMT1 and UHRF1. Cells were treated with or without MS-275 and UHRF1 (B) or DNMT1 (C) immunoprecipitates were blotted with the indicated antibodies. (D) UHRF1 ubiquitinates DNMT1. HEK 293 cells were transfected with the indicated plasmids. Antibodies against Myc immunoprecipitates were blotted with antibody against HA to detect ubiquitinated DNMT1. Myc-DNMT1D, DNMT1 mutant lacking the HAUSP-interacting domain. UHRF1DRING, UHRF1 with a RING domain deletion. (E) Knockdown of UHRF1 blocks HDACi-induced DNMT1 degradation. HEK 293 cells were transfected with control siRNA or siRNAs against UHRF1 and treated with or without MS-275. Western blotting was performed with the indicated antibodies. (F) Overexpression of UHRF1 leads to degradation of a DNMT1 mutant lacking the HAUSP-interacting domain (DNMT1D). Full-length DNMT1 or DNMT1D was cotransfected into HEK 293 cells with the indicated expression vectors. Cell lysates were blotted with the indicated antibodies. (G) DNMT1, HAUSP, UHRF1, HDAC1, and PCNA associate with Tip60. Flag-tagged Tip60 immunoprecipitates were blotted with the indicated antibodies.

     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

    HAUSP KO cells are more sensitive to HDACi-induced apoptosis.(A) HDAC inhibition induces apoptosis in HAUSP KO cells.HAUSP WT or KO cells were treated with or without MS-275 at the indicated concentration for 72 hours, then fixed and stained with propidium iodide. Flow cytometric analyses were used to profile sub-G1, G1, and G2-M cell populations. Apoptotic cells were quantified after the indicated clones were treated with either 5 or 10 μM MS-275. The means and SDs of three independent experiments were plotted (*P<0.001, t test). (B) HDAC inhibition induces apoptosis in HAUSP KO cells but leads to G2-M arrest in WT cells.Cell cycle profiles of HAUSP WT or KOcells that were treated or not with 5 μM MS-275. (C)HDAC inhibition increases the abundance of apoptotic cell markers. The indicated cells were treated with or without MS-275 for 72 hours.Cell lysates were blotted with antibodies against cleaved caspase 3 and β-actin. (D) Ectopic overexpression of DNMT1 in HAUSP KO cells suppresses apoptosis. HAUSP KO clones or HAUSP KO cells inducibly

    overexpressingDNMT1 were treatedwith 10 μM MS-275. Apoptotic cell populations were quantified by fluorescence-activated cell sorting (FACS) analyses (*P < 0.001, t test). Cell lysates from these cells were blotted with the indicated antibodies. (E) HDAC inhibition arrests the growth of HAUSP KO cells. DLD1, HAUSP KO, and KO cells ectopically expressing HAUSP were treated with the indicated concentration of MS-275 for 4 days. Cell numbers were determined and data from eight replicates were plotted (**P <0.001, t test). (FandG) HDACi inhibits tumor xenograft formation ofHAUSP KOcells.Athymic nudemice (five in each group)were injectedsubcutaneously and bilaterallywith cells of the indicated genotypes. Mice were treated with or without MS-275 at 15mg/kg for 4 weeks. Tumors were harvested and photographed (F). Tumor sizes of the indicated groupsweremeasuredweekly and theaveragevolumes at each timepoint were plotted (G).MANOVA analyses were performed to determine whether there was an overall difference of the tumor sizes, as well as whether there was a difference in development over time of tumor sizes between the two groups (P < 0.0001).
     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

  • Numerous APC (+) oligodendrocytes (middle upper panel) with ellipsoid nuclei labeled with Sytox (left upper panel) were observed in 8 week old Thy-1 mitoCFP control MONs. NF-200 (+) neurofilaments extended along the MON as linear individual fibers (right upper panel). A period of OGD (60 min) caused a significant loss of APC (+) oligodendrocytes, a gain in the appearance of pyknotic nuclei (dense, brighter nuclei, white arrows, OGD panel), and loss of NF-200 (+) axon structures, which were, replaced with axonal head and bulb formation (white asterisks). Pretreatment with SAHA (1uM) or MS-275 (1uM) effectively preserved APC (+) oligodendrocytes, together with numerous linear individual NF-200 (+) axons. Note fewer pyknotic nuclei (white arrows, SAHA and MS-275 panels) after OGD in MONs treated with SAHA or MS-275.

    J Neurosci 2011 31, 3990-9. Entinostat (MS-275) purchased from Selleck.

    Notch1ICD, Notch2ICD, and Notch3ICD were transduced into human aortic SMCs, which were then treated with HDAC inhibitors TSA or MS-275 or with vehicle DMSO (con). The top 2 rows are different exposures of the same blot to detect the epitope tags on the N ICD constructs. Longer (top row) and shorter ( second row) exposures are shown because t he level of N2ICD expression was lower than that of N1ICD and N3ICD. SMC markers were analyzed and were similarly induced by activation of each Notch r eceptor. Both TSA and MS-275 significantly suppressed the induction of SMC proteins by Notch activation.

    J Am Heart Assoc 2012 1, e000901. Entinostat (MS-275) purchased from Selleck.

  • LSD1 and HDAC inhibitors exhibit synergistic growth inhibition. Cells were simultaneously treated with pargyline or HDAC inhibitors for 48 h.

     

     

    Breast Cancer Res Treat 2012 131, 777-789. Entinostat (MS-275) purchased from Selleck.

    Histone acetylation in the spinal cord after HDACI treatment. Histone acetylation in the lumbar spinal cord of mice receiving i.t. SAHA (25 μg) or MS-275 (0.5 μg) for 30 min was analyzed by immunoblot (A, B) and immunofluorescent histochemistry (C) for antigens indicated. Animals receiving i.t. saline were used as control. Images of the H3K9/18ac signals in the left half of the lumbar spinal cord are shown in the first row in C. Immunosignals of indicated antigens in the superficial dorsal horn are presented in the rest rows in C.

    Mol Pain 2010 6, 51. Entinostat (MS-275) purchased from Selleck.

  • B. Confluent quiescent foreskin fibroblasts were treated with HDAC1 inhibitor or vehicle for 24 hours. Type I procollagen protein levels in whole cell lysates were determined by immunoblotting. A representative result of three independent experiments is shown. The band density was evaluated by densitometry. C. Under the same conditions, mRNA levels of the α1(I) collagen (COL1A1) gene were determined using reverse transcription quantitative real-time PCR. The graph represents -fold change in COL1A1 mRNA levels in comparison to unstimulated controls, which were arbitrarily set at 100. The mean and SD from three separate experiments are shown. * p<0.05 versus control cells treated with vehicle.

    PLoS One 2013 8, e74930. Entinostat (MS-275) purchased from Selleck.

    Inhibition of LSD1 activity by HDAC inhibitors. a MDA-MB-231 and MDA-MB-468 cells were exposed to indicated HDAC inhibitors for 24 h.

     

     

    Exp Dermatol 2010 19, 1096-1102. Entinostat (MS-275) purchased from Selleck.

  • HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h, and their expression of GRP78, PERK-eIF2α axis and ATF4, ATF3, CHOP and DR5 proteins.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Entinostat (MS-275) purchased from Selleck.

    HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h. ATF4, ATF3, CHOP and DR5 proteins were measured by Western blot.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Entinostat (MS-275) purchased from Selleck.

  •  

    HDAC inhibition increases SMN-luciferase reporter mRNA levels. qRT-PCR was used to measure increases of SMN-luciferase mRNA following treatment with HDAC inhibitors. Fold increase of mRNA was normalized to GAPDH.

    Biochem Bioph Res Co 2010 414, 25-30. Entinostat (MS-275) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-20μM MS-275 was added.

     

     

    2011 Dr. Zhang of Tianjin Medical University. Entinostat (MS-275) purchased from Selleck.

产品安全说明书

HDAC抑制剂选择性比较

生物活性

产品描述 Entinostat (MS-275)强烈抑制HDAC1HDAC3,无细胞试验中IC50分别为0.51 μM和1.7 μM,抑制作用强于HDACs 4, 6, 8,和10。Phase 3。
靶点
HDAC1 [2]
(Cell-free assay)
HDAC3 [2]
(Cell-free assay)
0.51 μM 1.7 μM
体外研究

MS-275通过作用于2′-氨基而抑制HDACs。MS-275作用于 K562细胞,诱导 p21WAF1/CIP1和凝溶胶蛋白的累积。MS-275作用于A2780细胞,可以降低S期细胞,提高G1期细胞。 MS-275通过抑制HAD而抑制人类肿瘤细胞系,包括 A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St和 HCT-15细胞增殖, IC50 为41.5 nM到4.71 μM。[1]MS-275抑制HDACs,作用于HDAC1和 HDAC3时IC50 分别为0.51 μM和1.7 μM。而对其他的HDACs没有抑制效果,如HDAC4, 6, 8和10。[2]MS-275有效抑制人类白血病和淋巴癌细胞,包括U937, HL-60, K562, 和Jurkat。MS-275可以诱导U937细胞p21CIP1/WAF1 调节的生长和变异Marker (CD11b)的表达。MS-275降低cyclin D1和抗凋亡蛋白Mcl-1与XIAP的表达。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SCC-3 NUPUVW1HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojZTWM2OD1yLkC2NUDPxE1? NUPVSFg{W0GQR1XS
ALL-PO MofRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXq4Z5p[UUN3ME2wMlA3OzV3IN88US=> MXfTRW5ITVJ?
697 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYSxfYxUUUN3ME2wMlA6QTd4IN88US=> NF;sXmtUSU6JRWK=
NCI-H748 NYrjUItQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTzUWhtUUN3ME2wMlExOzN2IN88US=> Mkj4V2FPT0WU
NKM-1 NFLNcFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4H2SmlEPTB;MD6xNFkyOiEQvF2= NXHUfY1OW0GQR1XS
ES1 M4j2U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLkVmtUUUN3ME2wMlEyOjV3IN88US=> NHPUTGtUSU6JRWK=
NCI-H1963 NGfFcGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHj[Wh3UUN3ME2wMlEyPTd7IN88US=> NVHRPZdWW0GQR1XS
NCI-H1417 M37HRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nxT2lEPTB;MD6xNlk4PCEQvF2= NYrDVVNCW0GQR1XS
NEC8 MoHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPCTWM2OD1yLkGzOVI4KM7:TR?= M1fBTHNCVkeHUh?=
CRO-AP2 M1PEXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\FbHNKSzVyPUCuNVY5QDlizszN MXXTRW5ITVJ?
A3-KAW NHq2SGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPXTWM2OD1yLkG3OlI4KM7:TR?= M3X5PHNCVkeHUh?=
SF539 M2DIbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonNTWM2OD1yLkG5OVk{KM7:TR?= M1n1VnNCVkeHUh?=
NOS-1 NGTxRlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnKwTWM2OD1yLkG5OlE6KM7:TR?= NVjMeohZW0GQR1XS
NTERA-S-cl-D1 NF;uUpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjBVlZKSzVyPUCuNlAyOTNizszN NILBOmVUSU6JRWK=
COR-L88 NXTPTnlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPyXYFoUUN3ME2wMlIzQTV7IN88US=> MYXTRW5ITVJ?
EM-2 M{L2TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTBwMkSwO|kh|ryP NETXXmdUSU6JRWK=
KARPAS-45 MmXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTBwMke4N|Mh|ryP Mm\WV2FPT0WU
DSH1 Mlm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3[0fmlEPTB;MD6yPFcxQCEQvF2= MUfTRW5ITVJ?
HT-144 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zGT2lEPTB;MD6zNFI2PiEQvF2= NGH5c25USU6JRWK=
ATN-1 M3XIb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvi[oxKSzVyPUCuN|A2PzZizszN NIPnXVhUSU6JRWK=
HEL MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWixZ4JCUUN3ME2wMlMyOzR6IN88US=> MWLTRW5ITVJ?
NB12 MmPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTBwM{G3OVYh|ryP M1XDcnNCVkeHUh?=
LU-139 MlrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33KbmlEPTB;MD6zN|UyKM7:TR?= NFP2[oRUSU6JRWK=
J-RT3-T3-5 MkjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTBwM{O3NVYh|ryP NEPqbZNUSU6JRWK=
MOLT-13 NFruW2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1e1UGlEPTB;MD6zN|gyKM7:TR?= Mlv4V2FPT0WU
SR NWXNeXlnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTBwM{SyOlEh|ryP NG\jdppUSU6JRWK=
CMK MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlj5TWM2OD1yLkO1O|I4KM7:TR?= MoXGV2FPT0WU
ES8 NYTUW3V5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;CTWM2OD1yLkO2NFIzKM7:TR?= M3\UT3NCVkeHUh?=
LB647-SCLC NIHa[2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfiTWM2OD1yLkO2O|Mh|ryP NGDzS4RUSU6JRWK=
TE-8 M1TtPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vFXmlEPTB;MD6zOlk{PSEQvF2= NY\vdGRmW0GQR1XS
BV-173 MmfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEGxToJKSzVyPUCuN|cyOjFizszN NIDUeWxUSU6JRWK=
DEL MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\JO2lEPTB;MD6zO|Q5PyEQvF2= MW\TRW5ITVJ?
ARH-77 NFHmNJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTBwM{ixPVMh|ryP MX3TRW5ITVJ?
NCCIT NU[1VG11T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4C4dWlEPTB;MD6zPFY1QSEQvF2= NEPhNmhUSU6JRWK=
RPMI-8402 NUPEdGJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DEPGlEPTB;MD6zPFcxOSEQvF2= NUjFS5NFW0GQR1XS
MONO-MAC-6 MmTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PzeGlEPTB;MD6zPFc4PiEQvF2= MYXTRW5ITVJ?
SK-MM-2 NES4eFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;PRmlEPTB;MD6zPVg3QCEQvF2= NEjRcVZUSU6JRWK=
CHP-126 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPK[GJiUUN3ME2wMlQxOjNzIN88US=> MlzqV2FPT0WU
A101D MknoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV:0[o9kUUN3ME2wMlQxOyEQvF2= NWP2NIZsW0GQR1XS
SCH NYjBcFV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkG5TWM2OD1yLkSwN|QzKM7:TR?= M4DWXnNCVkeHUh?=
NMC-G1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\4cGlEPTB;MD60NFM3PyEQvF2= MX7TRW5ITVJ?
NCI-H209 MlLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLSTVBKSzVyPUCuOFA3OTNizszN MYDTRW5ITVJ?
MOLT-16 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfvN3c5UUN3ME2wMlQyODF5IN88US=> M1fPOnNCVkeHUh?=
RPMI-6666 NGLXVpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;RbWlEPTB;MD60NVEzKM7:TR?= MknZV2FPT0WU
OPM-2 NVXTbmY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGezO5FKSzVyPUCuOFE2OTNizszN M4jLNnNCVkeHUh?=
MRK-nu-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HJV2lEPTB;MD60N|E2OyEQvF2= Mor3V2FPT0WU
BC-1 NIHQWJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPxTWM2OD1yLkSzOFA{KM7:TR?= NF;5UHlUSU6JRWK=
MHH-NB-11 NYX5[4RMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW[zRnUyUUN3ME2wMlQ{PDV|IN88US=> NWPNemRnW0GQR1XS
Ramos-2G6-4C10 NVn0[VE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk[4TWM2OD1yLkSzPFk4KM7:TR?= NXOxfYlRW0GQR1XS
LS-513 NVLWVJpsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrEepM{UUN3ME2wMlQ1PTBzIN88US=> NF\RfppUSU6JRWK=
K5 NUfl[3luT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\QTWM2OD1yLkS3NFI2KM7:TR?= MoXFV2FPT0WU
HOP-62 NV3KT4dOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV:4THN2UUN3ME2wMlQ5OzV6IN88US=> Mo\XV2FPT0WU
NCI-H187 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfVe4NDUUN3ME2wMlQ6OjJ5IN88US=> NYnMUXg1W0GQR1XS
BE-13 M37E[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTBwNEm2OlEh|ryP MkPsV2FPT0WU
HC-1 NX7RfWF1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGX2NpFKSzVyPUCuOVA1PzNizszN M1Twd3NCVkeHUh?=
ACN MkXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrWV41KSzVyPUCuOVExOjhizszN MV7TRW5ITVJ?
HCC1599 MnPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLuOVZPUUN3ME2wMlUyPTdizszN NYrmRoc3W0GQR1XS
MV-4-11 NYm1e5RbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33LPWlEPTB;MD61N|A1OSEQvF2= Mo\YV2FPT0WU
LC-2-ad MnjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTDTWM2OD1yLkWzOlY{KM7:TR?= MXnTRW5ITVJ?
HL-60 NVTjbHRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7VSXlKSzVyPUCuOVQzPjFizszN NELtfllUSU6JRWK=
NB17 NIXlc21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTBwNUSzPEDPxE1? NIPPUVRUSU6JRWK=
TE-1 Ml\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTBwNUWzNFYh|ryP M1vWOXNCVkeHUh?=
NCI-H524 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn[4TWM2OD1yLkW1OFAyKM7:TR?= M33ibXNCVkeHUh?=
MZ7-mel MmHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLac5dKSzVyPUCuOVYyODVizszN NID3VFBUSU6JRWK=
L-363 NF60ZppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTBwNU[2OVch|ryP M1fQWnNCVkeHUh?=
BL-41 NGrNWlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHQXI04UUN3ME2wMlU3QDh7IN88US=> NXPCSo01W0GQR1XS
LU-134-A MlzhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jkSGlEPTB;MD61O|A4OyEQvF2= NEHsfJJUSU6JRWK=
SIG-M5 NGW5dnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXvdmtLUUN3ME2wMlU4QDR6IN88US=> M1HjcHNCVkeHUh?=
ONS-76 NXPPcXB3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mny4TWM2OD1yLkW4NlQzKM7:TR?= NH;Z[GlUSU6JRWK=
KARPAS-299 NXnZZ2NrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HWTGlEPTB;MD61PFUxPCEQvF2= NFzLVllUSU6JRWK=
DU-4475 M2rHOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTBwNUi3NFMh|ryP MXfTRW5ITVJ?
NB69 MmDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXSb2prUUN3ME2wMlU6QDJ3IN88US=> MnjrV2FPT0WU
MHH-PREB-1 M2faPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnq0TWM2OD1yLk[wO|E6KM7:TR?= MYrTRW5ITVJ?
LU-165 NEf3R5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\WTWM2OD1yLk[xPFEzKM7:TR?= MknPV2FPT0WU
LOUCY MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PGXWlEPTB;MD62N|M3PCEQvF2= NEf6[ZdUSU6JRWK=
NCI-H526 MmPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfETWM2OD1yLk[zOVQyKM7:TR?= M3\RT3NCVkeHUh?=
KE-37 M{OwN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DmVmlEPTB;MD62OFI4PiEQvF2= M3K4Z3NCVkeHUh?=
NALM-6 MljyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33WbWlEPTB;MD62OFg3KM7:TR?= NVvsdVR4W0GQR1XS
CW-2 M{jyNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXGTWM2OD1yLk[1O|k1KM7:TR?= NVnnU25qW0GQR1XS
SU-DHL-1 NInlTY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrvRnZKSzVyPUCuOlU6PDdizszN MoP3V2FPT0WU
NB13 NVjEZWxLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTBwNk[4NVch|ryP NIXmVI5USU6JRWK=
QIMR-WIL Mkj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHRNmhKSzVyPUCuOlg{PDNizszN MmDpV2FPT0WU
ECC12 M{TYcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn:wTWM2OD1yLkewNFg3KM7:TR?= NYPtOnRtW0GQR1XS
KALS-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDQSmJKSzVyPUCuO|A1QTJizszN MV\TRW5ITVJ?
COR-L279 NWj5RXh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH:4WVdKSzVyPUCuO|A6QTZizszN NVux[3E{W0GQR1XS
NB14 NWXqSYQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHOzb3FKSzVyPUCuO|I3OTdizszN NXiwZlN7W0GQR1XS
CCRF-CEM MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWr1TZBFUUN3ME2wMlc1PjZzIN88US=> MnHSV2FPT0WU
SW954 NHTxfVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLZTWM2OD1yLke1PVk6KM7:TR?= MUjTRW5ITVJ?
IST-SL1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXKT5N1UUN3ME2wMlc4OzR6IN88US=> NYrXXldjW0GQR1XS
LAMA-84 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTBwN{e1Olch|ryP NYqweYw3W0GQR1XS
Daudi MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFr6dYJKSzVyPUCuO|c3QDFizszN MlHBV2FPT0WU
BC-3 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWftVW1WUUN3ME2wMlc5OzB6IN88US=> MWjTRW5ITVJ?
HCC2998 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3noW2lEPTB;MD63PFM3KM7:TR?= NHTpPJBUSU6JRWK=
NCI-H69 NFjOVIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTvWWZVUUN3ME2wMlgxOTR5IN88US=> NEe5d3BUSU6JRWK=
CPC-N MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzXWYlKSzVyPUCuPFA2OjRizszN MljGV2FPT0WU
NOMO-1 NWm5c4NzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\aV2lEPTB;MD64NVA5PCEQvF2= NVXwRYs2W0GQR1XS
CESS M1;0Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlP6TWM2OD1yLkixNVk4KM7:TR?= MnrYV2FPT0WU
LC4-1 NH;5eIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvWTWM2OD1yLki0NFA4KM7:TR?= Mm[xV2FPT0WU
BL-70 M2ftXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETXS4pKSzVyPUCuPFU4ODJizszN M{HyTXNCVkeHUh?=
ES4 NWLoVIE6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTBwOEW4Olgh|ryP NHj0PWRUSU6JRWK=
HCE-T NF2z[2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTBwOEexO|Eh|ryP NYHwTXVIW0GQR1XS
JAR MlHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfjXndKSzVyPUCuPFc5OjdizszN MoTXV2FPT0WU
ST486 NXSxN45{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEG4NFFKSzVyPUCuPFc6OTdizszN MX3TRW5ITVJ?
KS-1 NGXIRoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\lOpNKSzVyPUCuPFgxQTZizszN NFrSVVJUSU6JRWK=
GDM-1 NWPRTHUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUiyR|M6UUN3ME2wMlg5Pjh5IN88US=> M{P4eHNCVkeHUh?=
EHEB NHfTUZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlj1TWM2OD1yLkmyOVg2KM7:TR?= NVnRWY5JW0GQR1XS
LB2518-MEL NETubXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTBwOUOyPFQh|ryP NWr5O|ZCW0GQR1XS
GOTO MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fBZWlEPTB;MD65OVA4PiEQvF2= NFjhXZpUSU6JRWK=
LXF-289 M4ni[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7KeZhKSzVyPUCuPVU6ODFizszN NF3YSodUSU6JRWK=
ES6 NWfBSHVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnOVWM{UUN3ME2wMlk3PDN5IN88US=> NVTZbXdYW0GQR1XS
OS-RC-2 M1zIb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDyRmdKSzVyPUCuPVY5OyEQvF2= Mo\mV2FPT0WU
DMS-153 MkXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fhTmlEPTB;MD65O|Q3QSEQvF2= M1;TRXNCVkeHUh?=
SK-PN-DW MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTBwOUe4N|Eh|ryP NEjXSVhUSU6JRWK=
HH NXPqSWNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXOeGdOUUN3ME2wMlk5QTV7IN88US=> MnH2V2FPT0WU
SH-4 NIG3UItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfOUHBKSzVyPUGuNFI1OSEQvF2= NFTjNGNUSU6JRWK=
MOLT-4 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPQNY9GUUN3ME2xMlA{PDV2IN88US=> M3XRb3NCVkeHUh?=
TGW MkPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTFwMEe2O|Uh|ryP MYfTRW5ITVJ?
L-540 M1[3PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTFwMUC2NFQh|ryP NY\6O2VqW0GQR1XS
PF-382 M2D1fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\HNWlEPTB;MT6xNVUyOyEQvF2= MXTTRW5ITVJ?
LC-1F M3zMemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3pTWM2OD1zLkGyNFA4KM7:TR?= Mn:wV2FPT0WU
OVCAR-4 NUPwZ5liT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7lTWM2OD1zLkGzNVY2KM7:TR?= M2e3Z3NCVkeHUh?=
A4-Fuk M4TmSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPrO21bUUN3ME2xMlE2OzZ2IN88US=> MYPTRW5ITVJ?
HCC2218 MnrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTBVmJKSzVyPUGuNVY3PDFizszN M2[4NXNCVkeHUh?=
HAL-01 MmrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLYTWM2OD1zLkG2PVQ{KM7:TR?= MUnTRW5ITVJ?
IST-MEL1 NXvVc|FUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLUOm1KUUN3ME2xMlE4PjV7IN88US=> NE\tV3dUSU6JRWK=
NCI-H719 NXHxTY9YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVSzc4xNUUN3ME2xMlE4QDl6IN88US=> Mm\4V2FPT0WU
EVSA-T NYPB[pVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDBdJhJUUN3ME2xMlE5OTF2IN88US=> M3zURXNCVkeHUh?=
SK-NEP-1 NGDVb3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTRRpFKSzVyPUGuNlAzPjZizszN NInTdY5USU6JRWK=
OCUB-M M3fTZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnL0TWM2OD1zLkKxOFg6KM7:TR?= MmO4V2FPT0WU
MEG-01 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTFwMkKxNVgh|ryP NXPOO4g3W0GQR1XS
no-10 MlnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvETWM2OD1zLkKzNVEzKM7:TR?= MkW4V2FPT0WU
MHH-CALL-2 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\aS2lEPTB;MT6yOFczOSEQvF2= MXTTRW5ITVJ?
SK-N-DZ M2iwZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;TXI92UUN3ME2xMlI1Pzd4IN88US=> M2HwNHNCVkeHUh?=
SCLC-21H NEjPbItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVS3TGp7UUN3ME2xMlI3PDd6IN88US=> MWTTRW5ITVJ?
CTV-1 M3HBOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1yyfWlEPTB;MT6yO|QzPSEQvF2= NGLWZopUSU6JRWK=
NB1 MlzJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfS[XFKSzVyPUGuNlc4OzJizszN MkO3V2FPT0WU
NCI-H64 NHruR2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELmNohKSzVyPUGuNlg1PjJizszN NGTjNXZUSU6JRWK=
MDA-MB-134-VI NX3rZmpLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTFwMki1O|ch|ryP Mn7DV2FPT0WU
LB2241-RCC NE[1clZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoThTWM2OD1zLkK4OlY{KM7:TR?= NVq3c3c5W0GQR1XS
8-MG-BA NU\idIYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzWSI1KSzVyPUGuNlg5PjZizszN NHXpOYJUSU6JRWK=
LP-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLzTWM2OD1zLkK5PVQ4KM7:TR?= M4TqTXNCVkeHUh?=
LS-411N NYm0Rno4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWf4[YlmUUN3ME2xMlMxQTl6IN88US=> Mm\ZV2FPT0WU
CAL-148 NFjYS3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDESIJKSzVyPUGuN|I2PDJizszN MlvrV2FPT0WU
NCI-H2171 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HVcWlEPTB;MT6zOFUxOiEQvF2= MkizV2FPT0WU
JiyoyeP-2003 NYfFe|JOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnVc5lOUUN3ME2xMlM2OzlizszN NUi1[oVvW0GQR1XS
NCI-H2107 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HmeWlEPTB;MT6zOVg5OyEQvF2= NUPOXmlYW0GQR1XS
BB30-HNC NXPp[ppyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTFwM{i5O|gh|ryP M3zy[nNCVkeHUh?=
K-562 M3ryV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPpdFdKSzVyPUGuN|kzOTlizszN MXXTRW5ITVJ?
PSN1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofuTWM2OD1zLkSyNlg4KM7:TR?= MkL0V2FPT0WU
HCC2157 NWXwdZJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTFwNEK2PVEh|ryP MYLTRW5ITVJ?
SBC-1 NUm5dm1rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn20TWM2OD1zLkSyO|QyKM7:TR?= NHuycINUSU6JRWK=
MC116 M1zhTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljkTWM2OD1zLkSzOlE2KM7:TR?= NVXkcJlEW0GQR1XS
KARPAS-422 MorTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;NNGlEPTB;MT60OVM2QCEQvF2= NXryUnpTW0GQR1XS
LB996-RCC NVPIeJdUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLjTWM2OD1zLkS3NVA{KM7:TR?= Mly4V2FPT0WU
MSTO-211H NGrYZmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPCPGJYUUN3ME2xMlQ4QTh5IN88US=> MWLTRW5ITVJ?
BT-474 NHnLVIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFX2NFdKSzVyPUGuOVE4PjRizszN MoTrV2FPT0WU
A388 NVLEVW5bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3hUmNJUUN3ME2xMlUyQTR3IN88US=> Mn3FV2FPT0WU
SJSA-1 M1TDfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTFwNUKyOkDPxE1? NXyxS2FmW0GQR1XS
COLO-829 NUjEXFByT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nuTGlEPTB;MT61N|U3PCEQvF2= M3m4RXNCVkeHUh?=
KM-H2 M1:3Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7tT4pKSzVyPUGuOVY3PyEQvF2= M4TjSHNCVkeHUh?=
GR-ST MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfIRo9VUUN3ME2xMlU3QDJizszN MWjTRW5ITVJ?
RPMI-8866 MojiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3W3d2lEPTB;MT62NFE1PCEQvF2= M17TfnNCVkeHUh?=
KG-1 Mn7jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2O1bWlEPTB;MT62NVkxOSEQvF2= MlLBV2FPT0WU
NCI-H82 Mn\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofyTWM2OD1zLk[zOFA3KM7:TR?= M1:1SnNCVkeHUh?=
LB1047-RCC NEfRXXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfMd5J4UUN3ME2xMlY{PDV7IN88US=> MVjTRW5ITVJ?
KM12 NGWzNXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{X5fGlEPTB;MT62OFch|ryP MlmzV2FPT0WU
NB5 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDKTWM2OD1zLk[1Olc4KM7:TR?= NF75TIVUSU6JRWK=
HDLM-2 M1HGfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELFdFBKSzVyPUGuOlgzQDFizszN MnPiV2FPT0WU
KU812 MnLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPJb3dKSzVyPUGuOlk3ODVizszN NIjqXoFUSU6JRWK=
DB NIjXNY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTFwN{CzOVMh|ryP NXH3XXhWW0GQR1XS
HD-MY-Z NV\TU|RHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jnSmlEPTB;MT63OVI{PCEQvF2= MYfTRW5ITVJ?
KURAMOCHI MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLlN3ZrUUN3ME2xMlc4OjB5IN88US=> MYTTRW5ITVJ?
ETK-1 NW\wfYZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPQRXFKSzVyPUGuO|g5PzlizszN MUXTRW5ITVJ?
SK-UT-1 NYLvOGRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTHTWM2OD1zLke5N|g5KM7:TR?= M1W2WXNCVkeHUh?=
HUTU-80 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTFwN{m1NFgh|ryP M{DUTHNCVkeHUh?=
ES7 NEPZepBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XrbmlEPTB;MT64NFMxOiEQvF2= MoXBV2FPT0WU
SW872 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPhTWM2OD1zLkixN|k2KM7:TR?= MWfTRW5ITVJ?
TK10 NHHE[2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTVXGdKSzVyPUGuPFMyODhizszN NE\lSoRUSU6JRWK=
LB831-BLC MlzES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTFwOEO1OlMh|ryP NFW4e4VUSU6JRWK=
TE-9 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PRUGlEPTB;MT64OFQzOiEQvF2= MWjTRW5ITVJ?
MLMA MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\QTWM2OD1zLki4NlM1KM7:TR?= MkfwV2FPT0WU
D-542MG MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\xPHpKSzVyPUGuPFk{PzNizszN NECyU5dUSU6JRWK=
EW-16 M3TGfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTFwOUK3NkDPxE1? NFrCPXZUSU6JRWK=
LOXIMVI MnrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLKTWM2OD1zLkmzNlgh|ryP NY\hcVJJW0GQR1XS
GB-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjaTWM2OD1zLkmzPFY3KM7:TR?= MUPTRW5ITVJ?
IST-SL2 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTmTWM2OD1{LkCwNlYzKM7:TR?= MVXTRW5ITVJ?
LAN-6 NGSzXZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTJwMEG5OlYh|ryP MoP2V2FPT0WU
NCI-H510A MnjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHJRoNKSzVyPUKuNFQ2ODJizszN M3XCO3NCVkeHUh?=
NCI-H1092 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M32zcWlEPTB;Mj6wOVEzPCEQvF2= NHf3SGxUSU6JRWK=
HT MnHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUThOpFIUUN3ME2yMlExPDV2IN88US=> MYjTRW5ITVJ?
RL95-2 NYXPSXdCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mme3TWM2OD1{LkGxOFgzKM7:TR?= NXi2d4h2W0GQR1XS
NCI-H1355 M3K1O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTJwMUG3PVIh|ryP MVzTRW5ITVJ?
NCI-H720 NYn2bXU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4T2Z2lEPTB;Mj6xOlg4OyEQvF2= MnXEV2FPT0WU
NCI-H1522 MoL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlm0TWM2OD1{LkKxO|I{KM7:TR?= M1K2OXNCVkeHUh?=
LB373-MEL-D MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrHTWM2OD1{LkK2PVAzKM7:TR?= MlTSV2FPT0WU
DG-75 NEH2XY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPGOIlKSzVyPUKuNlcyPDhizszN NVnTNGRFW0GQR1XS
ML-2 MkjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjPZYhmUUN3ME2yMlMzQDV3IN88US=> MVXTRW5ITVJ?
SF126 NEPNXHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTJwM{OwPVQh|ryP MnH6V2FPT0WU
MPP-89 M4XROmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTJwM{OxOFUh|ryP MYfTRW5ITVJ?
NCI-H345 Mo\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnKxTWM2OD1{LkOzNlc4KM7:TR?= NWX1PFFGW0GQR1XS
LS-123 NH3MfGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;VTWM2OD1{LkO0PVM3KM7:TR?= Ml7GV2FPT0WU
NB10 M{fPRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHkTWM2OD1{LkSxNFkzKM7:TR?= NYf2WI5YW0GQR1XS
CGTH-W-1 NHOyb3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PnfWlEPTB;Mj60NlI3PyEQvF2= M3HO[nNCVkeHUh?=
CP66-MEL NUKxXI16T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYSzfYF7UUN3ME2yMlQ4PzdizszN NFzlbYRUSU6JRWK=
L-428 M{\GN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjHPFEzUUN3ME2yMlQ5PTJzIN88US=> NVnqSIlCW0GQR1XS
DMS-79 M2XKNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DoS2lEPTB;Mj61OFExOyEQvF2= NWDLRVFMW0GQR1XS
NCI-H1882 NY\xeGxWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\sNm5KSzVyPUKuOlc2PjJizszN M3\sdnNCVkeHUh?=
KGN NULiXWk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrjPY1KSzVyPUKuO|Y5PzZizszN NUXXTXB6W0GQR1XS
EW-1 NFX3TZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEOxVnJKSzVyPUKuO|cxQDNizszN NHnmOplUSU6JRWK=
U-266 M1LkS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLRSYRxUUN3ME2yMlg1QDJ|IN88US=> M3HmRXNCVkeHUh?=
COLO-320-HSR M2nL[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTJwOEW2OFEh|ryP MmXxV2FPT0WU
KMOE-2 NWnwRZJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\jTWM2OD1{Lki3O|EyKM7:TR?= MlPNV2FPT0WU
BB49-HNC M1vY[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrVeYNtUUN3ME2yMlkzPDhizszN NEHuZlFUSU6JRWK=
GI-1 Mn3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXHdYdKSzVyPUKuPVI6PTdizszN MV\TRW5ITVJ?
NCI-H1304 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUG3co0zUUN3ME2zMlAxPTFzIN88US=> MkjXV2FPT0WU
NCI-H2227 NGLq[lJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrQRZFKSzVyPUOuNFIxPzlizszN MlWxV2FPT0WU
U-87-MG MkjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrkNG1ZUUN3ME2zMlA{PTF|IN88US=> M4TnS3NCVkeHUh?=
NCI-H747 MlSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXXSXhZUUN3ME2zMlA2OjB4IN88US=> M13KVHNCVkeHUh?=
CTB-1 MljJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTNwMEWzO|Yh|ryP NFjIT3NUSU6JRWK=
RPMI-8226 MlrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTNwMUSzO|gh|ryP M2D3[3NCVkeHUh?=
NCI-H2141 MmHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjmfZdKSzVyPUOuNVY2PjZizszN NXmz[lQ1W0GQR1XS
IST-MES1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7uTHZqUUN3ME2zMlE5Ojd7IN88US=> Mnn0V2FPT0WU
TE-5 NV\PcmxOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTNwMkGzOFIh|ryP M336RXNCVkeHUh?=
UACC-257 NX\xem1uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{C4cGlEPTB;Mz60N|Y2QSEQvF2= NYCz[5pbW0GQR1XS
SK-N-FI M1LPVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEey[lZKSzVyPUOuOFUzOjdizszN MmfYV2FPT0WU
MFH-ino MnWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mln4TWM2OD1|LkS2OVg6KM7:TR?= NYjJ[445W0GQR1XS
SF268 NYPiU3piT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEm0c5FKSzVyPUOuOFgyPzRizszN M3rzeHNCVkeHUh?=
TE-12 MoXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HqS2lEPTB;Mz61NVY6QSEQvF2= MlK4V2FPT0WU
NB6 M2\YTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofrTWM2OD1|LkW1OVY{KM7:TR?= MnnCV2FPT0WU
DJM-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnFTWM2OD1|LkW5PFk6KM7:TR?= MVLTRW5ITVJ?
MZ1-PC NInScYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fBc2lEPTB;Mz62NVYzPCEQvF2= NYfWTXpiW0GQR1XS
OCI-AML2 NYPXR5BXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTNwNkK2O|Eh|ryP MkfFV2FPT0WU
NCI-H1155 MmjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU[1WlhEUUN3ME2zMlcxQTR5IN88US=> MmPhV2FPT0WU
RKO MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HZOmlEPTB;Mz63O|E5QSEQvF2= NFTnVWVUSU6JRWK=
ECC4 Mn3hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDTOI4zUUN3ME2zMlk4OTl3IN88US=> MnXXV2FPT0WU
BB65-RCC NEHPVXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXDSWJKSzVyPUOuPVc2PDdizszN MmTIV2FPT0WU
EB-3 NE\hXldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTNwOUm2N|Mh|ryP NFiwRmZUSU6JRWK=
SHP-77 NEXTcVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7rTWM2OD12LkCwOVI1KM7:TR?= M4\3[nNCVkeHUh?=
NCI-H2196 M2n4T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\qTWM2OD12LkC1OlI2KM7:TR?= NUC4ZVRoW0GQR1XS
GI-ME-N NF34[45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLITWM2OD12LkC2N|k6KM7:TR?= MnraV2FPT0WU
MN-60 MkTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHTTWM2OD12LkGwPFch|ryP NIX1N4dUSU6JRWK=
NCI-H1694 NYH3RXFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLmTWM2OD12LkGzOFA2KM7:TR?= MnHQV2FPT0WU
LU-65 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvHTWM2OD12LkG1N|MzKM7:TR?= NHHTeFRUSU6JRWK=
NCI-H1436 Mmq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXmTWM2OD12LkG4N|M{KM7:TR?= MVjTRW5ITVJ?
KINGS-1 NWHRV4IzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHf5NXZKSzVyPUSuN|E1OzJizszN MoPBV2FPT0WU
GT3TKB NWLKc3NlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\NRphKSzVyPUSuN|MzPjhizszN M4r5SHNCVkeHUh?=
Becker NGPhRo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLuTWM2OD12LkO3N|EzKM7:TR?= NU\ueXE4W0GQR1XS
HCC1187 Mo\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnDfYVrUUN3ME20Mlg6PjV5IN88US=> Mlq1V2FPT0WU
D-502MG MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk[0TWM2OD13LkCwOFE3KM7:TR?= NXz6enJnW0GQR1XS
VA-ES-BJ NGfMfVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\ofVZHUUN3ME21MlE{Pzd6IN88US=> MWTTRW5ITVJ?
NB7 M3:4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHBTWM2OD13LkG0NVEzKM7:TR?= NWTPbVVDW0GQR1XS
SW962 MlXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYGzN3ZJUUN3ME21MlM5QDF2IN88US=> M{PPVnNCVkeHUh?=
no-11 M2P1WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPiO4lKSzVyPUWuO|Y{PDNizszN M1i4W3NCVkeHUh?=
KNS-81-FD NWrPV5JVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4L3XmlEPTB;NT65NFY6PCEQvF2= MVLTRW5ITVJ?
COLO-684 MlLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zjc2lEPTB;NT65PVQ6PCEQvF2= MkPkV2FPT0WU
D-263MG NGnrPJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn:0TWM2OD14LkC4PFk2KM7:TR?= NUXWbohyW0GQR1XS
EW-24 NF\KbHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTZwMki1NUDPxE1? NYfjbXJlW0GQR1XS
TE-10 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjMdY9KSzVyPU[uOFI3OjNizszN NWHm[nNKW0GQR1XS
EKVX NUDWe|FCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;ZfZNxUUN3ME22MlQ3OzJzIN88US=> MXTTRW5ITVJ?
NCI-H1648 M4\aSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLZU5dKSzVyPU[uOlc2PTdizszN MYXTRW5ITVJ?
LB771-HNC NXHP[JFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrnWJM4UUN3ME22MlkzOzBzIN88US=> MVLTRW5ITVJ?
SK-MEL-1 M{jFZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnG[GFjUUN3ME24MlE{OTZ4IN88US=> M4nNRnNCVkeHUh?=
COLO-668 MnjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojGTWM2OD16LkK3O|g3KM7:TR?= MUHTRW5ITVJ?
EW-12 NXzhWVIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRThwNEC4NFMh|ryP NUHTWXFwW0GQR1XS
A253 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DMemlEPTB;OD64OFY3OSEQvF2= Mn7nV2FPT0WU
NCI-H2126 NFTaPZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRThwOEmzNVkh|ryP NXKwRYlVW0GQR1XS
Calu-6 NGnLXpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRThwOUmwOFIh|ryP NX\W[4piW0GQR1XS
NCI-H23 MlvCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTlwMUe3OFYh|ryP MkPlV2FPT0WU
WSU-NHL M4W2dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHL0UFlKSzVyPUmuO|c1PzhizszN M2rtbnNCVkeHUh?=
MMAC-SF Mn;FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnKPJNKSzVyPUmuPVc6ODRizszN Mn;IV2FPT0WU
SK-LMS-1 MnviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33JZWlEPTB;MUCuNlg{PCEQvF2= MULTRW5ITVJ?
GCIY NH7heHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTFyLkW5NlQh|ryP Mmi5V2FPT0WU
TE-15 NVjEfpJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPETWM2OD1zMT62NFA1KM7:TR?= MoXsV2FPT0WU
EoL-1-cell M{PmVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTFzLke2PFIh|ryP M1LQSHNCVkeHUh?=
NCI-H2081 NU\vVI9[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLiUmYxUUN3ME2xNU44Pzh4IN88US=> M{\menNCVkeHUh?=
EW-3 NHTVc41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVn6V5BoUUN3ME2xNk4zPDZ|IN88US=> MkD6V2FPT0WU
CAS-1 NYrt[Xd1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vSTGlEPTB;MUKuN|Y{OSEQvF2= M3u4XHNCVkeHUh?=
C2BBe1 NECwSHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PLeWlEPTB;MUKuOlE{OSEQvF2= NHGycopUSU6JRWK=
D-247MG NIfxRo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnHZWZsUUN3ME2xNk44QTV{IN88US=> MUjTRW5ITVJ?
NCI-SNU-5 NInMbodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4[2S2lEPTB;MUKuPFAyOyEQvF2= M3X6OHNCVkeHUh?=
LS-1034 NF6wUpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXGeXJKSzVyPUG0MlM6PzVizszN MkHwV2FPT0WU
EW-18 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTF2LkS0PEDPxE1? NHnadXVUSU6JRWK=
Raji MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGK4OIZKSzVyPUG0MlUxPDlizszN MYDTRW5ITVJ?
D-283MED MnLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7adZdFUUN3ME2xOE43OjdzIN88US=> M2\qSHNCVkeHUh?=
MZ2-MEL NWPQfm1DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTF2Lkm2PVYh|ryP NUHDc4s5W0GQR1XS
NCI-SNU-16 NEXTZ25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXaR5dKSzVyPUG1MlQ3OzNizszN MWHTRW5ITVJ?
P30-OHK MmjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XOdGlEPTB;MUeuO|g{OSEQvF2= NEmyb|JUSU6JRWK=
RXF393 NUfTb2RmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGmzNY1KSzVyPUG5MlAyQDZizszN MXXTRW5ITVJ?
NCI-H1395 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33ZXGlEPTB;MkCuOlcxOyEQvF2= NIDC[2NUSU6JRWK=
U-698-M NInONHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXrTWM2OD1{MD63NFc2KM7:TR?= MXHTRW5ITVJ?
NCI-SNU-1 NYj0cG9ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWX6[|N3UUN3ME2yNE44OjJ|IN88US=> M2HMWnNCVkeHUh?=
SW684 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvOTWM2OD1{MT6xO|E3KM7:TR?= M4HlfnNCVkeHUh?=
NCI-H716 NGHxW2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInwU5ZKSzVyPUKxMlMyPTRizszN MlS4V2FPT0WU
JVM-2 NIXXSlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTJzLkSxN|Mh|ryP M{jWdXNCVkeHUh?=
NCI-H1581 MkPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PPUGlEPTB;MkKuOFE1QCEQvF2= NWK5UHRCW0GQR1XS
CA46 M1q2PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLVTWM2OD1|MT62PVM3KM7:TR?= Mmf1V2FPT0WU
SNB75 NYnNWnM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPv[llKSzVyPUOzMlY2ODNizszN Ml31V2FPT0WU
KNS-42 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1S1bGlEPTB;M{WuPVYzPCEQvF2= MXvTRW5ITVJ?
TUR NEXRSWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HidWlEPTB;M{[uNFUzOSEQvF2= M2rBNnNCVkeHUh?=
REH NF\jWodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3TTWM2OD1|Nz64NlEyKM7:TR?= MYnTRW5ITVJ?
EW-22 NXnpNVZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPBTWM2OD12Mj6yPFg2KM7:TR?= M{\tXnNCVkeHUh?=
NCI-H446 NYXLU4ZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjjXoRKSzVyPUSyMlc5PTNizszN NETtTHBUSU6JRWK=
ES3 NF[2cpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTR|LkGzN|kh|ryP M3[4Z3NCVkeHUh?=
EW-11 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fhSWlEPTB;NESuPFIyQCEQvF2= MnLFV2FPT0WU
RH-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LIXmlEPTB;NEeuOVgyOiEQvF2= M{jlV3NCVkeHUh?=

... Click to View More Cell Line Experimental Data

体内研究 MS-275按49 mg/kg剂量作用于除了HCT-15的人类移植瘤都显示出强抗癌活性。[1]MS-275促进恶性实体瘤和恶性血液病的治疗可能性,及生理和畸变基因表达的调节。[4]MS-275和IL-2联用,作用于肾细胞癌显示出强抗癌活性,因为降低调节性T细胞和增强脾细胞的表达。[5]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[6]
+ 展开

标准HDAC实验:

用HDAC buffer按1:6稀释鼠肝内的酶。重组人类HDACs按1:4稀释在HDAC buffer中。用于标准HDAC实验,60 μl HDAC buffer和10 μl 稀释的酶溶液在30oC混合。在HDAC buffer中加入30 μl基底液开始HDAC反应,随后在30oC下温育30分钟。加入100 μl胰蛋白酶溶液终止反应,胰蛋白酶溶液由溶于50 mM Tris-HCl(pH 为8.0)的10 mg/ml 胰蛋白酶, 100 mM NaCl,及 2 μM TSA组成。30oC下温育20分钟, 通过测定460纳米(λex = 390 nm)处的荧光监测AMC的释放。使用释放的AMC校准荧光强度 。用于标准时间过程实验,在初始100 μl HDAC 反应中加入20 pmol 基底物。2-50 pmol 基底物的酶法分析产物获得荧光AMC,通过测量这种荧光AMC来测定 Km值和 Vmax值。使用Hanes 图分析实验数据。记录的AMC信号是针对没有酶而有buffer和基底物的空白区。
细胞实验:[2]
+ 展开
  • Cell lines: A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St和HCT-15细胞
  • Concentrations: 10 μM 左右
  • Incubation Time: 3天
  • Method: 5×103个肿瘤细胞接种到96孔板上,加入梯度浓度MS-275培养三天。细胞用0.1 mg/mL中性红在CO2反应器中染色1小时,测定中性红与50 μL乙醇和150 μL 0.1 M Na2HPO4溶解后的OD540,测定IC50值。
    (Only for Reference)
动物实验:[1]
+ 展开
  • Animal Models: 侧腹皮下注射A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1和Calu-3细胞的裸鼠
  • Formulation: 溶于0.05 N HCl, 0.1% Tween-80
  • Dosages: 12.3, 24.5和49 mg/kg
  • Administration: 每天口服处理一次,每周进行5天,持续4周。
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 75 mg/mL (199.25 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
2% DMSO+30% PEG 300+ddH2O
10mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 376.41
化学式

C21H20N4O3

CAS号 209783-80-2
稳定性 powder
in solvent
别名 SNDX-275

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03179930 Recruiting Lymphoma|Relapsed|Refractory Memorial Sloan Kettering Cancer Center|Merck Sharp & Dohme Corp.|Syndax Pharmaceuticals June 7 2017 Phase 2
NCT03250273 Recruiting Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreactic Cancer Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Syndax Pharmaceuticals|Bristol-Myers Squibb November 6 2017 Phase 2
NCT02453620 Recruiting Breast Adenocarcinoma|HER2/Neu Negative|Invasive Breast Carcinoma|Metastatic Malignant Solid Neoplasm|Stage III Breast Cancer AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7|Unresectable Solid Neoplasm National Cancer Institute (NCI) November 6 2015 Phase 1
NCT03473639 Recruiting Metastatic Breast Cancer|Breast Cancer University of Virginia|Syndax Pharmaceuticals September 30 2018 Phase 1
NCT02936752 Recruiting Blasts 21-30 Percent of Bone Marrow Nucleated Cells|Myelodysplastic Syndrome|Previously Treated Myelodysplastic Syndrome National Cancer Institute (NCI) April 3 2017 Phase 1
NCT00101179 Active not recruiting Acute Myeloid Leukemia|Chronic Myelomonocytic Leukemia|de Novo Myelodysplastic Syndrome|Leukemia|Myelodysplastic Syndrome|Previously Treated Myelodysplastic Syndrome|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndrome|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) November 3 2004 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    I would like to use Entinostat(Catalog No.S1053) for animal study. What is your recommendation for the solvent? What is the role of PEG 300 in this case? Can I use DMSO only and dilute it with PBS or HBSS?

  • 回答:

    2%DMSO/30%PEG/68%Water is recommended. PEG is an important polymer that helps with the solubility of hydrophobic drugs. If you use DMSO only and dilute it with PBS or HBSS, Entinostat will likely to precipitate out since it has very low solubility in water.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

相关HDAC产品

Tags: 购买Entinostat (MS-275) | Entinostat (MS-275)供应商 | 采购Entinostat (MS-275) | Entinostat (MS-275)价格 | Entinostat (MS-275)生产 | 订购Entinostat (MS-275) | Entinostat (MS-275)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID